Semaglutide 10mg: clearing up the biggest misconception about this dose

The myth: 10mg is a Wegovy dose you can work up to

It is a reasonable assumption. Medications often scale in round numbers, and if you know semaglutide comes in several strengths, a 10mg step sounds plausible. But the Wegovy injection schedule does not include it. The weekly injection pathway starts at 0.25mg (a tolerability dose while your body adjusts) and moves through 0.5mg, 1mg, 1.7mg, and 2.4mg, which was the standard maintenance dose for several years. In January 2026 the MHRA approved a higher maintenance option, eventually leading to a dedicated 7.2mg single-dose pen approved on 14 April 2026. That is where the licensed injection schedule currently ends. No step involves 10mg.

The confusion most often traces back to Rybelsus, an oral semaglutide tablet made by Novo Nordisk for people with type 2 diabetes. Rybelsus comes in 3mg, 7mg, and 14mg strengths, none of which is 10mg either, though the general idea of oral semaglutide in higher doses may blur in online discussions. You can read more about how semaglutide works across its different licensed forms if that broader context helps.

The short version: if a seller or source refers to a 10mg semaglutide dose for weight loss, that is a red flag worth taking seriously, given that no such step exists within the licensed schedule. The MHRA has warned repeatedly about counterfeit and unlicensed weight-loss products circulating online; anything outside the licensed schedule should be treated with scepticism and reported via the MHRA's Yellow Card scheme.

What the actual oral semaglutide weight-loss schedule looks like

In June 2026 the MHRA approved the first oral GLP-1 medicine for weight management in the UK, Wegovy tablets, also made by Novo Nordisk. This is a different formulation from Rybelsus: it uses an absorption enhancer called SNAC to get semaglutide into the bloodstream through the gut wall, and it carries its own distinct dose schedule designed for weight management rather than diabetes.

The Wegovy tablet ladder is 1.5mg, 4mg, 9mg, and 25mg, with at least a month at each level before moving to the next, as assessed by a prescriber. The 25mg maintenance dose is where the trial evidence was gathered. In the OASIS 4 trial (64 weeks, 307 adults with obesity or overweight and at least one weight-related condition), participants lost on average around 13.6% of their body weight compared with roughly 2.4% on placebo. Among those who stayed fully adherent to treatment, the figure was closer to 17%. Those numbers are meaningful, and they are built around the licensed 25mg maintenance dose, not any intermediate 10mg step.

One practical note: unlike the injection, tablets need no refrigeration. You take one each morning on an empty stomach with a small amount of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. For people who prefer not to inject, it changes things considerably. If you want to explore the evidence in more detail, the full semaglutide prescribing information is a useful starting point.

Who is likely to be considered for semaglutide, and what a prescriber actually weighs up

Both Wegovy injection and Wegovy tablets are licensed for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. Meeting those numbers is the starting point, not the end of the conversation.

A prescriber also needs to know about your current medicines, your medical history, and whether any contraindications apply. Semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. People with a personal or family history of certain thyroid conditions, or a history of pancreatitis, need particular care. The NHS semaglutide medicines page sets out the key considerations in plain language.

For context on how NICE has positioned semaglutide within NHS weight management, it is worth knowing that the Wegovy injection is recommended under NICE appraisal TA875, though NHS access through specialist services typically involves waiting lists. Private routes through a regulated pharmacy allow clinically suitable adults to access treatment without a referral, subject to assessment. Details of what that process involves at a service like ours are on the weight-loss treatment overview.

Side effects worth knowing, especially at higher doses

Semaglutide's side-effect profile is well documented. Gastrointestinal symptoms dominate: nausea, loose stools, constipation, indigestion, and sometimes vomiting. These tend to surface most noticeably when starting treatment or after a dose increase, and most people find them settle over a couple of weeks. Staying well hydrated and eating smaller meals helps. Fatigue and headache are also reported, less frequently.

There are symptoms that warrant prompt medical attention. Severe, persistent stomach pain (especially pain that spreads to the back, with or without vomiting) may indicate pancreatitis. In January 2026 the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines. Gallbladder symptoms, significant dehydration from persistent GI illness, and allergic reactions all also need prompt assessment. Never self-adjust your dose or timing in response to side effects; that conversation belongs with your prescriber.

If you are curious about lower dose steps and how the titration works in practice, the 1mg stage or the 2mg level pages cover those points in more detail. And if you are weighing up what a private prescription actually costs and what it includes, the treatment pricing page has an honest breakdown, no subscriptions, no hidden fees.